Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth
NCT06934655Phase 3Recruiting
- Sponsor
- Children's Hospital Los Angeles
- Start
- Sep 2026
- Primary completion
- Nov 2030
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide in pediatric obesity (2 arms), sponsored by Children's Hospital Los Angeles. Primary endpoint: Percent Body Mass Index at 24 months. Started Sep 2026; status: recruiting.
02
Drugs
03
Conditions
pediatric obesity
Beyond the preview
Go deeper on NCT06934655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06934655.